Overview of Nosca Mereprine

Property	Description
Active Ingredient	Noscapine (Noscapine hydrochloride)
Form	Oral tablets, Oral syrup
Pharmacological Class	Antitussive (Cough suppressant)
Common Use	Symptomatic treatment of dry/non-productive cough
Origin	Derived substance (Alkaloid from Papaver somniferum)

What Type of Medicine is Nosca Mereprine?

Nosca Mereprine is an orally administered medication that is specifically classified within the antitussive pharmacological group, functioning as a cough suppressant. Its active ingredient, Noscapine (INN), achieves its effect via a central mechanism on the cough reflex.

This formulation is defined by its primary ingredient's unique profile: Noscapine is a non-narcotic and non-opioid substance. This classification means the substance suppresses the cough without producing the dependence, euphoria, or significant respiratory depression associated with traditional narcotic cough suppressants.

Composition and Origin of Noscapine

The active ingredient, Noscapine, is a substance of natural origin, chemically defined as a benzylisoquinoline alkaloid derived from the opium poppy (Papaver somniferum). Nosca Mereprine is consistently marketed as a single-ingredient product, concentrating its therapeutic effect solely on cough suppression.

The medication is supplied for oral use in two main dosage forms: a liquid syrup preparation and solid oral tablets. The availability in both syrup and tablet forms supports flexible administration across various target age groups. The chemical entity itself is structurally defined as a phthalideisoquinoline alkaloid, establishing its unique molecular fingerprint.

Nosca Mereprine's General Purpose

The overall purpose of Nosca Mereprine is the targeted symptomatic treatment of a cough that is non-productive—meaning it does not bring up mucus or phlegm. It is intended to alleviate the discomfort and disruption caused by persistent, irritating, or tickling sensations that stimulate the cough reflex. The general benefit is the reliable management of the cough stimulus, thereby helping to interrupt the annoying cycle of a persistent dry cough.

What side effects are possible with Nosca Mereprine?

Nosca Mereprine, which contains the active ingredient Noscapine, is generally well-tolerated when used as directed for the short-term symptomatic relief of a dry cough.

Common and Less Common Side Effects

Like all medicines, this drug can cause side effects, although not everybody gets them. The most commonly reported side effects are mild and transient.

System	Common Side Effects	Less Common Side Effects (Seek Medical Advice if Severe)
Central Nervous System	Drowsiness, Headache, Dizziness	Confusion, Agitation, Hallucinations
Gastrointestinal	Nausea, Vomiting, Constipation	Acute abdominal pain (cramps)
Cardiovascular		Increased heart rate
Immune System		Allergic reactions (rash, swelling, difficulty breathing)

If you experience any severe side effects, signs of a serious allergic reaction, or symptoms of overdose (e.g., severe drowsiness, respiratory depression, or seizures), seek immediate medical attention.

Contraindications and Important Safety Information

Do not use Nosca Mereprine if you have a known allergy to noscapine or any other ingredient, or if you have respiratory insufficiency or asthmatic cough. It is generally not recommended for use in children under 6 years of age and should be used with caution in the elderly.

Drug Interactions: Noscapine may interact with other medications. Consult your doctor or pharmacist if you are taking:

Anticoagulants (e.g., Warfarin, Acenocoumarol) due to a potential increase in their effects and risk of bleeding.
Central Nervous System (CNS) depressants (e.g., sedatives, hypnotics, alcohol) as this may enhance drowsiness and sedation.
Monoamine Oxidase Inhibitors (MAOIs), as the combination may cause unknown and potentially harmful effects.

Since this medication may cause drowsiness, caution is advised when driving or operating machinery.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes specific signs and required actions related to Nosca Mereprine (Noscapine) overdose. Overdose may present with a spectrum of Central Nervous System (CNS) effects, including Dizziness, Confusion, Agitation, and Hallucinations. More severe and life-threatening documented outcomes include profound CNS depression leading to Coma, Seizures, and Respiratory failure.

Required Emergency Actions

The most serious manifestations, such as Coma or Respiratory failure, require immediate professional intervention. Regulatory guidance explicitly mandates that individuals experiencing severe symptoms must Contact emergency services immediately or Seek immediate medical attention. Supportive management is the mainstay of the officially described treatment, consisting of Symptomatic and supportive care alongside Hospital monitoring or Close intensive care monitoring for profound intoxication cases.

Documented Overdose Considerations

Officially documented risks include severe allergic manifestations, such as Angioedema or Laryngeal oedema, which require emergency care due to airway compromise. Regulatory documents also note that Elderly patients are a population identified as being at an increased risk for Respiratory failure in the context of an overdose.

Therapeutic Uses of Nosca Mereprine

What Nosca Mereprine Treats: Main Uses and Benefits

The therapeutic application of Nosca Mereprine is focused strictly on symptomatic management and is used in areas where short-term symptom management is appropriate for dry cough.

Relief of Irritating, Non-Productive Cough

Nosca Mereprine is generally used for the symptomatic relief of a dry cough—a non-productive manifestation that does not clear mucus. It is applied across domains where additional symptomatic support is needed, primarily focusing on cough. It helps address symptom clusters related to persistent, exhausting coughs and the frustrating tickling sensation that triggers recurrent episodes. This supportive relief is commonly used across conditions presenting with acute episodes, such as those seen during the common cold or influenza.

Reduction of Symptom Burden and Functional Strain

This medication is applied in scenarios where additional management of discomfort is required, particularly when the cough symptoms that interfere with daily functioning create noticeable physiological strain. The treatment provides supportive relief when symptoms interfere with routine activities, relevant when symptoms become more disruptive during flare-ups, such as when they interrupt sleep.

Quick Fact: Relief for Disruptive Cough Nosca Mereprine is applied in contexts where the dry cough is intense and interferes with routine activities or where symptoms create noticeable physiological strain.

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Nosca Mereprine

This section outlines the official eligibility and non-eligibility requirements for Nosca Mereprine as specified in government regulatory documents.

Contraindications (Must Not Use)

Population/Condition	Restriction
Hypersensitivity	Known allergy to the active substance (noscapine) or any excipients.
Age	Children under 6 years old (specifically for the syrup formulation).
Respiratory Status	Patients with respiratory insufficiency or asthmatic coughing.

Restrictions and Special Considerations

Use of Nosca Mereprine is not recommended in several key populations:

Pregnancy and Lactation: Use should be avoided by women who are pregnant or currently breastfeeding.
Older Adults (Elderly): Special caution and potential dosage adjustment may be necessary due to potential changes in drug metabolism.

If you fall into any of the restricted or contraindicated groups, you should not use this medicine.

What should I know about interactions with other medicines?

Nosca Mereprine's interaction profile, as defined in official regulatory documents, is structured around specific metabolic pathway inhibition and additive pharmacodynamic effects. The information focuses on documented restrictions and resulting exposure changes, not general safety.

Interaction Type	Interacting Substance/Class	Official Interaction Outcome
Formal Contraindication	Monoamine Oxidase Inhibitors (MAOIs)	Prohibition due to documented risk of unforeseen and potentially fatal effects.
Pharmacokinetic	Coumarin Anticoagulants (e.g., Warfarin, Acenocoumarol)	Increases the anticoagulant effect, resulting in an officially documented increase in the International Normalized Ratio (INR).
Pharmacokinetic	CYP2C9 & CYP3A4 Substrates	Noscapine is a formal inhibitor of Cytochrome P450 2C9 and 3A4, causing increased plasma concentrations or reduced clearance of co-administered medicines dependent on these enzymes.

Pharmacodynamic and Substance Interactions

Co-administration with other Centrally Sedating Substances (such as hypnotics or certain antihistamines) or Alcohol is noted in regulatory documents to carry the risk of enhanced sedative effects or increased drowsiness. This is classified as a pharmacodynamic interaction resulting from an additive effect on the central nervous system.

The regulatory profile explicitly notes that there are no mandatory dose-timing separation rules or population-specific interaction cautions (such as for hepatic impairment or the elderly) documented across major official labels.

Mechanism of Action

Nosca Mereprine (Noscapine) exerts its primary mechanism of action as a sigma receptor agonist. This interaction occurs within the central nervous system, specifically targeting sigma receptors, which are non-opioid, non-GABA, and non-glutamatergic. The agonism of these receptors modulates neuronal activity in the medulla oblongata, leading to a downstream physiological consequence of decreased responsiveness in the cough reflex center.

Independently, the compound also modulates cellular dynamics through binding to tubulin subunits, thereby altering microtubule assembly. This interaction subtly destabilizes the dynamic instability of microtubules, interfering with cellular processes reliant on the microtubule network. This modulation can lead to a cell-cycle arrest at the G2/M phase in proliferating cells and subsequent activation of apoptotic pathways, including the mitochondrial (intrinsic) cascade involving cytochrome c release and caspase activation. Furthermore, it has demonstrated an ability to inhibit endothelial cell migration, which is linked to its modulation of anti-angiogenic pathways.

Dosage and Administration Information

How Nosca Mereprine is Used: Official Administration Guidelines

Nosca Mereprine, containing the active ingredient Noscapine, is administered via the oral route for its antitussive (cough suppressant) effect. This medication is available as both an oral syrup and oral tablets or capsules. The use of this drug is designated for short-term symptomatic management.

Administration Details and Dosage Rules

Established guidelines define a structured pattern of use that specifies dosing based on age and a mandatory daily limit.

Administration Scope	Official Instruction
Route of Administration	Primarily Oral for antitussive effect.
Frequency Pattern	Administered in divided use, typically three to four times daily (every 4–6 hours).
Timing in Relation to Meals	Can be taken with or without food.
Duration of Use	Intended for short-term symptomatic relief.

The drug's total intake is controlled by strict maximum dose limits that must not be exceeded within a 24-hour period. For adults, the typical single dose ranges from 15 mg to 30 mg, which is repeated in the divided-use pattern. The maximum total daily dose for adults should generally not exceed 180 mg.

Population-Specific and Procedural Rules

Usage is tied to specific age criteria. Pediatric use is authorized starting at certain ages (such as from age 2 or 6 depending on the specific product labeling), with corresponding lower dose ranges. For instance, children aged 6 to under 12 receive lower single doses compared to adults.

If a dose is missed, instructions advise against doubling the dose; the missed dose should be skipped if it is almost time for the next scheduled dose. For liquid formulations, a specialized dose-measuring device must be used to ensure accurate administration.

Recent Clinical Evidence

Research evidence / Overview of Studies for Nosca Mereprine

Evidence for Acute Dry, Non-Productive Cough

Research has explored symptom patterns in patients experiencing acute dry cough. Studies were conducted during periods of increased symptom activity, such as cough associated with the common cold or other upper respiratory tract infections. The evidence base includes short-term Randomized Controlled Trials (RCTs) and controlled clinical evaluations, which were used to measure outcomes related to acute dry cough. These studies included populations of adults experiencing non-productive cough, and they measured outcomes related to physical discomfort. Researchers measured subjective metrics like cough frequency and intensity and examined patient-reported outcomes describing perceived discomfort using tools like the Visual Analogue Scale (VAS).

Studies report how symptoms evolved in the observed populations, typically over brief treatment periods lasting up to 5 to 14 days. Studies monitored measured cough symptoms and used comparative evidence against other antitussive agents. However, when examining all over-the-counter antitussives together, systematic reviews have described patterns where the findings across trials were mixed or conflicting.

Evidence for Symptom Management of ACEI-Induced Cough

Separate research examined symptoms in a highly specific patient cohort: adults with hypertension who developed a persistent dry cough while taking certain blood pressure medications known as Angiotensin-Converting Enzyme Inhibitors (ACEI). This research was evaluated in clinical evaluations and observational studies focused solely on this medication-induced symptom. The studies monitored patient-reported outcomes related to perceived discomfort.

Study Duration and Research Gaps

Research exploring short-term symptom changes is relevant in trials assessing short-term or episodic symptom patterns. The available clinical evaluations and RCTs for acute dry cough were primarily limited to short-term monitoring, with most follow-up durations falling within a two-week period. Research provides limited insight into persistent cough symptoms that last beyond two weeks. Data for certain groups, such as children, remain insufficient in certain contexts, and long-term effects are not fully established. The overall certainty remains low for the general antitussive class due to heterogeneous findings across systematic reviews.

Frequently Asked Questions (FAQ)

Common questions about Nosca Mereprine (FAQ)

Q: Does Nosca Mereprine affect the results of any common lab tests?

Official information indicates that Nosca Mereprine is an inhibitor of certain liver enzymes, specifically CYP2C9 and CYP3A4. For patients taking anticoagulant medications like warfarin, this mechanism is associated with a potential for an increase in the International Normalized Ratio (INR), a common blood test used to measure clotting time.

Q: Can I take Nosca Mereprine if I am already taking supplements?

Regulatory documents note that this drug can affect the body's processing of other substances that rely on the same liver enzymes for metabolism (CYP2C9 and CYP3A4). This means there is a potential for interaction with certain supplements or herbal products, and official labeling references the importance of reviewing co-administered substances that may share these metabolic pathways.

Q: Is Nosca Mereprine a controlled substance?

Official classification defines Nosca Mereprine as a non-narcotic, non-opioid substance. This classification indicates that the medicine is not associated with the potential for abuse, dependence, or euphoric effects, which is typically the reason for a drug to be designated as a controlled substance.

Q: Is Nosca Mereprine generally well-tolerated?

The official product information describes the medicine as generally well-tolerated when used as directed. When side effects are reported, authoritative sources state that the most commonly reported effects are typically mild and transient (temporary), such as drowsiness or headache.

Q: Why do official documents mention 'unknown risk' for Nosca Mereprine in certain groups?

The most stringent warnings relate to combining the drug with Monoamine Oxidase Inhibitors (MAOIs). Official documents list this combination as a formal contraindication due to a documented risk of unforeseen and potentially fatal effects. This is a standard warning for medicines that affect the central nervous system when combined with MAOIs.

Q: What defines the 'maximum recommended use period' for Nosca Mereprine?

The official labeling designates the medicine for short-term symptomatic relief only, reflecting its intended use for temporary symptoms like those associated with a cold or flu. Clinical studies assessing the drug's effectiveness were generally limited to short observation periods, typically up to 14 days.

Q: Why do doctors prescribe Nosca Mereprine instead of other available options?

The official classification notes Nosca Mereprine is a non-narcotic, non-opioid antitussive. This distinction is often a regulatory factor considered in comparison to cough suppressants that may contain opioid substances, which are associated with effects like dependence and respiratory depression.

Q: Does Nosca Mereprine treat the cause of the issue or just the symptoms?

According to official documentation, the drug is designated for the symptomatic treatment of a dry cough. This means the medicine is intended to alleviate the discomfort of the symptom itself, rather than addressing the underlying medical cause of the cough.

Q: What is the difference between Nosca Mereprine and other common medicines for the same condition?

Official information classifies Nosca Mereprine as a non-narcotic, non-opioid antitussive. This designation represents a key regulatory difference from certain other cough suppressants that may contain opioid or narcotic ingredients.

Q: Is Nosca Mereprine available without a prescription?

The regulatory status of Nosca Mereprine (Noscapine) varies internationally. In many regions, including parts of Europe and Canada, the medicine is classified and made available as an Over-the-Counter (OTC) drug, which can be purchased without a prescription.

Q: Do I need to change my diet while taking Nosca Mereprine?

Official labeling advises that the medicine can be taken with or without food, meaning no specific timing is required relative to meals. No general changes to diet are officially required, but caution is advised regarding co-administration with alcohol.

Q: Can Nosca Mereprine affect my sleep?

Yes, official documents list drowsiness as a common side effect of the medicine. This central nervous system effect is associated with affecting alertness or causing feelings of sleepiness during use of the medicine.

Q: Do certain medical conditions prevent someone from using Nosca Mereprine?

Yes, official regulatory documents list several conditions as contraindications, which are reasons a person must not use the drug. These include known allergy to the ingredients, pre-existing respiratory insufficiency, and suffering from an asthmatic coughing.

Q: Can Nosca Mereprine be used by children?

Use of the medicine is generally contraindicated, or not recommended, for children under 6 years of age. For children 6 years and older, the drug may be authorized for use with specific lower dosage ranges defined in the regional official labeling.

Q: Is Nosca Mereprine appropriate for older adults?

Official product information emphasizes the need for special caution in older adults (the elderly), and potential dosage adjustments may be necessary due to known changes in drug metabolism in this population.

Q: Has Nosca Mereprine been approved in other major countries besides the US/EU?

Yes, the active ingredient, Noscapine, is approved and marketed as an antitussive in various countries across Europe, Asia, and other regions, in addition to being referenced in US and EU regulatory monographs.

Q: What kind of research was done to approve Nosca Mereprine?

Regulatory approval is supported by clinical research, including short-term Randomized Controlled Trials (RCTs) and controlled clinical evaluations. These studies were used to measure patient-reported outcomes related to cough frequency and intensity.

Q: How is Nosca Mereprine different from a similar-sounding medicine I heard about?

Official product information classifies Nosca Mereprine as a non-narcotic, non-opioid antitussive. This designation is a key regulatory difference from certain other cough suppressants that may contain opioid or narcotic ingredients.

Q: Is Nosca Mereprine known to cause dependency?

Official classification notes the medicine is a non-narcotic, non-opioid substance. Therefore, it is not associated with dependency, addiction, or euphoric effects in the way that narcotic substances are.

Q: What does the patient information leaflet say about the key benefits of Nosca Mereprine?

Official patient documents describe the key benefit as the reliable, targeted symptomatic treatment of an irritating, non-productive dry cough. The general purpose is to alleviate discomfort and interrupt the annoying cycle of the persistent cough reflex.

Q: Where does the name Nosca Mereprine come from?

The drug is named after its active ingredient, Noscapine. This substance is naturally derived and chemically classified as a benzylisoquinoline alkaloid, originating from the opium poppy (Papaver somniferum).

Q: Does Nosca Mereprine have any black box warnings?

No, authoritative US regulatory sources do not list a Boxed Warning (sometimes called a Black Box Warning) for Nosca Mereprine. This warning represents the most serious safety measure required by the FDA.

How should Nosca Mereprine be stored and disposed of?

How to Store and Dispose of Nosca Mereprine

The storage and disposal requirements for Nosca Mereprine are based on official regulatory labeling to ensure product stability and public safety.

Official Storage Requirements

Condition	Requirement
Temperature	Store below 25 C.
Protection	Must be protected from light and moisture; keep the container tightly closed.
Child Safety	Keep out of the reach and sight of children at all times.
Packaging	Store in the original container to maintain environmental protection.

Disposal of Unused Medicine

Unused or expired Nosca Mereprine must be disposed of in accordance with local regulations for pharmaceutical waste. Do not dispose of the product in household trash or pour it down the sink or drain. Patients should return unused medication to a pharmacy or designated collection site for proper handling.

Nosca Mereprine